Dipipanone are indicated for the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated. Dipipanone is related to methadone and can be substituted for assorted opioids. The severe or irreversible adverse effects of Dipipanone, which give rise to further complications, include hypotension, hypotension, hependence, agranulocytosis, ischemic colitis, generalized chorea, hypersensitivity hepatitis. It may interact badly with monoamine oxidase inhibitors, which are substances found in some antidepressants and other medication.

Bumadizone is a non-steroidal anti-inflammatory drug exerting analgesic, antipyretic and anti-inflammatory properties. It has been studied in the treatment of rheumatoid diseases.

Talniflumate, a prodrug of niflumic acid, is a potent analgesic and anti-inflammatory drug that has been used for the treatment of rheumatoid diseases. Talniflumate was synthesized by the esterification of a carboxyl group of niflumic acid with the phthalidyl moiety, and it exerts activity in the body through conversion to niflumic acid. Talniflumate has been studied as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease, and asthma. However, development of these indications appears to have been discontinued. Talniflumate has been approved and marketed for almost 20 years in Argentina and selected other countries (excluding the United States, Europe, and Japan).

Cinmetacin is a synthetic non-steroidal anti-inflammatory agent that belongs to the class of heteroaryl acetic acid derivatives. The anti-inflammatory activity of cinmetacin is attributed to the inhibition of the enzyme prostaglandin synthetase. In addition to anti-inflammatory activity, cinmetacin also possesses analgesic and antipyretic properties. It is indicated in the management of pain and inflammatory in conditions such as rheumatoid arthritis, ankylosing spondylitis, and acute gout. Unfortunately, the clinical use of cinmetacin is seriously limited owing to adverse effects such as gastric ulceration and haemorrhage, the most frequent of all adverse effects pertaining to administration of NSAIDs

Propacetamol is a bioprecursor of paracetamol. It is rapidly hydrolyzed by plasma esterases and releases its constituent paracetamol by the end of its intravenous or intramuscular administration. Its metabolism is identical to that of paracetamol. It is used in post-operative care and is delivered by I.V. It is given if the patient is unable to take oral or rectally delivered paracetamol and non-steroidal anti-inflammatory drugs are contraindicated. The onset of analgaesia from propacetamol is more rapid than paracetamol given orally. 2 g of propacetamol are equivalent to 1g of paracetamol.

Chlorthenoxazine is a benzoxazine and nonsteroidal anti-inflammatory drug with antiinflammatory activity.

Aluminum flufenamate is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. Antiphlogistic pain reliever Opyrin (Aluminum flufenamate) was launched in Japan by Taisho Pharmaceutical in 1967.

1,6-Dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol (rimazolium, MZ-144) is an analgesic (non-narcotic). It proved to be effective in all the analgesic assays used (independently of the nociceptive stimulus applied) (hot plate, tail flick, writhing tests, Randall-Selitto test, tail clip, surgical pain) differing in this respect from the nonsteroidal antiinflammatory analgetics. Rimazolium lacks the capacity of producing opiate-like physiological dependence. Also rimazolium fails to show any indication of narcotic-like abuse liability by any of clinical assessments. Rimazolium is registered in Hungary under the brand name Probon. In Hungary among analgesics Probon is the first of choice especially in case of chronic pain accompanying chronic respiratory tract diseases.

Bucloxic acid, a nonsteroidal anti-inflammatory agent, which was studied to treat the chronic glomerular nephropathy.

Simetride is a non-narcotic analgesic, it is an ingredient of Kyorin AP2 (a combination of Simetride and Anhydrous Caffeine (40:1)) in Japan. Kyorin AP2 is used to treat low back pain, symptomatic neuralgia, headache, menstrual pain, pharyngalgia/earache due to inflammation, toothache, postoperative pain.